December 10, 2008 12:42 ET

Petroleum Communication Holdings Finalizes Purchase in Stem Cell Company

LARGO, FL--(Marketwire - December 10, 2008) - Petroleum Communication Holdings, Inc. (PTLC) Formerly "AIT Wireless, Inc." (PINKSHEETS: PTLC), announced last week it had entered into an agreement to acquire a 15% equity position in AmeReGen-ImmunoCure Corp. The company has now finalized the purchase.

Privately held AmeReGen-ImmunoCure has the technology and global exclusive manufacturing rights for the highest quality assured mass-production of CITA T-cell therapeutics for many of the hardest-to-treat cancers.

CITA therapy has become routinely available in the EU, but not yet approved by the FDA for use in the United States. With no ethical dilemmas, "adult T-stem cell" therapy utilizes a person's own blood T-cells, and boosts the cancer immune surveillance system to prevent, reject, or destroy advanced cancer with little if any side effects; even in cancer's clinically most advanced and problematic multi-drug resistant forms, called MDR+ cancer.

General information on AmeReGen BioPharmaceuticals Inc. and on AmeReGen ImmunoCure Corp. is available at www.stemcellsatwork.com.

The exclusive and proprietary (stem) cell manufacturing technologies leveraged by AmeReGen-ImmunoCure Corp. includes patented breakthrough inventions developed at Stanford University in Palo Alto, California, as well as in stem cell hot bed BioBay/Silicon Valley, California and other leading sites.

This non-cash stock transaction has an estimated value of nearly $300 million, and continues to diversify PTLC's holdings that represent major growth potential.

This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These include, but are not limited to, statements regarding the Company's plans, intentions and expectations. Forward-looking statements are based on the opinions and estimates of management at the time the statements are made. Such statements are inherently subject to a variety of risks, uncertainties and other factors that could cause actual results to differ materially from those expected or implied by the forward-looking statements. These factors include general economic and business conditions nationally, internationally and in the regions and countries in which we operate; demographic changes; technology changes; competition; changes in business strategy or development plans; our high leverage and our ability to access capital markets; our ability to attract and retain qualified personnel; existing governmental regulations. Given these factors, investor and analysts should not place undue reliance on forward-looking statements.